Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Lyudmila Bazhenova, J. Graeme Hodgson, Corey J. Langer, George R. Simon, Scott N. Gettinger, Sai-Hong Ignatius Ou, Karen L. Reckamp, Howard Jack West, Alberto Chiappori, Han A. Koh, Julian R. Molina, Alice Tsang Shaw, Jyoti D. Patel, Justin Peter Favaro, Jeff Haney, William Reichmann, David Kerstein, Victor M. Rivera, D. Ross Camidge
Institutions: Moores Cancer Center, ARIAD Pharmaceuticals (United States), Abramson Cancer Center, University of Pennsylvania, The University of Texas MD Anderson Cancer Center, Yale Cancer Center, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, City Of Hope National Medical Center, Moffitt Cancer Center, Kaiser Permanente, Mayo Clinic, Massachusetts General Hospital, University of Chicago, Oncology Specialists of Charlotte, University of Colorado Denver
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891020186